FRCPI J. Crowe MD

Learn More
In order to study the effect of clofazimine, a powerful antimycobacterial and antiinflammatory agent, 49 patients with active Crohn's disease were randomized to either corticosteroids plus clofazimine 100 mg daily (N=25) or to steroids and matching placebo (N=24). A total of 28 patients (58%) went into disease remission (clofazimine 16, placebo 12;P=NS)(More)
  • 1